Modification of tumor suppressor affects sensitivity to potential GBM treatment
Monday, August 13, 2012 - 19:00
in Health & Medicine
Biologists and oncologists have long understood that a protein called the epidermal growth factor receptor or EGFR is altered in at least 50 percent of patients with glioblastoma. Yet patients with glioblastoma either have upfront resistance or quickly develop resistance to inhibitors aimed at stopping the protein's function, suggesting that there is another signalling pathway at play.